Compare FuelCell Energy Inc (FCEL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? FuelCell Energy Inc trades at $18.58 (market cap $1.62B), while Regeneron Pharmaceuticals Inc trades at $673.99 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 43× FuelCell Energy Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals.
| FCEL | REGN | |
|---|---|---|
Market Cap | $1.62B | $69.66B |
Sector | Industrials | Health |
52-Week High | $36.01 | $812.27 |
52-Week Low | $3.92 | $542.52 |
Enterprise Value | $1.47B | $63.61B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $21.35, up 11.9% in the last 24 hours, reflecting high volatility amid recent news. The stock shows a neutral technical signal with bearish moving averages, while fundamentals reveal persistent losses with a net income margin of -132.41% in 2025 despite revenue growth to $158.16M. Recent developments include a strategic partnership with Siemens to scale clean power solutions and a $225M stock offering that caused temporary dilution concerns.
The outlook is mixed: analyst consensus is balanced with a $20.75 price target, but continued cash burn and high valuation multiples pose risks. Opportunities lie in AI-driven data center demand, though profitability remains a key challenge for sustainable upside.
Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.
Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
